The Company is scheduled to present on Tuesday, March 3 at 10:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at ...

Microplastics and nanoplastics are increasingly recognized as pervasive environmental contaminants that accumulate in animals ...

VivoSim Labs, Inc. (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the appointment of Dr. Arumugham (Ragoo) ...

Empowering People and Elevating Performance: Wellness Workdays Announces 2026 Conference Speakers The 13th Annual Emerging Trends in Workplace Wellness Conference will feature leading experts in ...

Two Boston community solar companies combined while pharma giants GSK and Eli Lilly made major biotech acquisitions in ...

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

Scoreboard at BLFC Matches at White Stadium with Collegium Branding · GlobeNewswire Inc. BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Aspire Biopharma’s new sublingual powder bypasses digestion, delivering alprazolam directly for faster anxiety and panic ...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the ...

In a significant step forward for mucosal immunity, Aptar Pharma has announced that its innovative nasal delivery systems are being utilized in CastleVax’s Phase II clinical trial for CVAX-01, an ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased ...